Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit www.sopherion.com.


'/>"/>
SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) ... in the development of pharmaceutical and consumer products, announces the operational numbers of ... 2017. Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... of their partnership to provide the Pharmacist eCare Plan to Computer-Rx ... the country with the ability to develop the Pharmacist eCare Plan, a shared ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric patients ... The Emergency Room opened early March, making it the first SignatureCare Emergency ... are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re glad ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/1/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... call will be broadcast live over the Internet on Thursday, ... release detailing the quarterly results will be made available at ... The live audio webcast can be accessed via ... will be archived for replay following the conference call. ...
Breaking Medicine Technology: